Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Result: At baseline, patient 2 harbored the rtA181T (4.7%), rtN236T (5.7%), rtL180M (12.5%), rtS202G (3.2%), and rtM204I/V (7%) substitutions, and other resistance mutations were present at low levels (<1%).
Result: At baseline, this patient carried with rtL180M (2.4%), rtM204I/V (3.4%), rtS202G (3.3%), rtA181V/T (4.7%), and
Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.
Result: Interestingly, residues W153Q, I169T, A200V, and S202G, which are related to LAM resistance, were found only in this group with a frequency between 3.3 and 9.9% (Table 2).
Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy.
PMID: 26889227
2016
Experimental and therapeutic medicine
Result: At this time, the viral strains of rtL180M + rtM204V + rtS202G, rtL180M + rtM204V + rtT184S and rtL180M + rtM204V + rtS202G + rtT184S were co-existent and represented 83% (25/30), 10% (3/30) and 7% (2/30) of the viral population, respectively.
Result: Prior to the virological break
Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.
Abstract: One patient developed virological breakthrough while bearing single, double, and triple (rtL180 M, rtM204 V, rtS202G) substitutions.
Result: At baseline, this patient displayed rtM204I/V (3.5%), rtL180 M (2.1%), and rtS202G (3.4%) substitutions, and the resistance and nonresistance mutations frequencies were significantly different (P = 0.011).
Result: Eight patients harbored rtM204I/V substitutions of at least 1% (ranging from 1% to 3.6%); 2 of these patients also prese
Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.
Method: Using the Mutation Reporter Tool software (http://hvdr.bioinf.wits.ac.za/mrt/), HBV resistance-associated mutations (RAMs) in the pol gene represented by V173L, L180M, A181V, A194T, S202G, M204V/I and N236T were assessed.
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).
Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.
Abstract: RESULTS: TDF susceptibilities of lamivudine-resistant clones (rtL180M/M204V) and lamivudine plus entecavir-resistant clones (rtL180M/S202G/M204V) were similar to wild type clones in vitro.
Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.
Result: Nevertheless, LMV-associated mutation rtM204V/I and rtL180M, LdT-associated mutation rtM204I, and ETV-associated mutations rtT184A/I/S, rtS202G and rtM250L didn't differ significantly between genotype B and C (P > 0.05).
Result: The rate of other drug-associated resistant mutation models, such as rtA181T+rtN236T for ADV, rtL180M+
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
Abstract: Once-daily peroral administration of CAdA reduced HBVETV-RL180M/S202G/M204V viremia (P = 0.0005) in human-liver-chimeric/ HBVETV-RL180M/S202G/M204V-infected mice, whereas ETV completely failed to reduce HBVETV-RL180M/S202G/M204V viremia.
Abstract: Southern analysis using Huh-7 cells transfected with HBV-containing plasmids demonstrated that CAdA was potent against both wild-type (IC50= 7.2 nM) and ETV-resistant HBV (IC50= 69.6 nM for HBVETV-RL180M/S202G/M204V), whereas ETV failed to reduce HBVETV-RL180M/
HBV mutation literature information.
PMID: 
2016
Oncotarget
Browser Board
Co-occurred Entities
Filtrator
ViMRT